Enzo Biochem Reports Validation of Three High Quality, Low Cost Biomarkers for Detecting Cancers & Their Progression, Especia...
July 18 2018 - 9:00AM
Business Wire
Enzo Biochem Inc. (NYSE:ENZ) today announced the validation of
three clinically relevant, cost-efficient biomarker detection tests
for charting the progression of various cancers, especially in the
field of women’s health. These cost effective, high quality primary
antibodies function with our full open system workflow and
complement Enzo’s strategy of introducing lower cost testing
solutions for the clinical laboratory market.
The validated tests complement Enzo’s POLYVIEW®
immunohistochemistry (“IHC”) and in situ hybridization (“ISH”)
detection platform, an enhanced diagnostic detection system used by
pathologists in reading tissue biopsies and favorably cited by a
leading peer review publication for showing no false positives.
The new biomarker tests are used in patient tissue samples with
elevated levels of three proteins: p16, which aids in the prognosis
of cervical cancer; K1-67, an important marker of cell
proliferation in different tumors, including cervical and
endometrial; and p53, instrumental in diagnosis of high grade
gastric, colonic, bladder, endometrial adenocarcinoma and serious
ovarian carcinomas.
In the case of the cellular protein p16, its overproduction is
closely correlated with Human papillomavirus (HPV) infections of
cells currently infecting 9 million Americans. HPV infections have
been linked to 90% of cervical and anal cancers, and 70% of
vaginal, vulvar and oropharyngeal (throat) cancers. Cervical cancer
alone accounts for 250,000 deaths per year worldwide, with the
highest incidence in the developing world and the underserved
population in the U.S.
The global cancer biomarkers market is projected to reach more
than $20 billion by 2022, up from $11.5 billion in 2017 with the
global IHC market projected to reach over $2 billion by 2021.
Primary biomarkers, including p16, K1-67 and p53 account for a
significant portion of the IHC market. Recent increases in the cost
of testing p16, K1-67, and p53 continue to negatively affect
clinical laboratory profit margins, especially when considering the
overall decrease in reimbursement. Enzo’s newly validated tests
offer a cost effect solution to this problem.
“As has been demonstrated by the study involving our POLYVIEW®
technology, high quality IHC reagents reduce false positive results
without compromising signal strength, and the validation of our
three biomarkers in combination with this platform offers reliable
high throughput staining capabilities with significant cost
savings,” said Elazar Rabbani, Chairman and CEO of Enzo. “Pairing
the p16 biomarker test, as well as the others, with our POLYVIEW®
IHC detection platform, now adapted to an automated workflow, is
another vital example of what Enzo is bringing to healthcare in
savings and efficiency with our disruptive technology as
reimbursement costs continue to shrink diagnostic lab margins.”
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and
intellectual property through the development of unique diagnostic
platform technologies that provide numerous advantages over
previous standards. A global company, Enzo Biochem utilizes
cross-functional teams to develop and deploy products, systems and
services that meet the ever-changing and rapidly growing needs of
health care today and into the future. Underpinning Enzo Biochem’s
products and technologies is a broad and deep intellectual property
portfolio, with patent coverage across a number of key enabling
technologies.
Except for historical information, the matters discussed in this
news release may be considered "forward-looking" statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended. Such statements include declarations regarding the intent,
belief or current expectations of the Company and its management,
including those related to cash flow, gross margins, revenues, and
expenses which are dependent on a number of factors outside of the
control of the Company including, inter alia, the markets for the
Company’s products and services, costs of goods and services, other
expenses, government regulations, litigation, and general business
conditions. See Risk Factors in the Company’s Form 10-K for the
fiscal year ended July 31, 2017. Investors are cautioned that any
such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that
could materially affect actual results. The Company disclaims any
obligations to update any forward-looking statement as a result of
developments occurring after the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180718005115/en/
For: Enzo Biochem, Inc.Steve Anreder,
212-532-3232steven.anreder@anreder.comorCEOcast, Inc.Michael Wachs,
212-732-4300mwachs@ceocast.com
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Apr 2023 to Apr 2024